An open‐label, phase 1, randomized, three treatments, three‐period, crossover, relative bioavailability study of CC‐292, a potent and orally available inhibitor of bruton tyrosine kinase.

What is known and objective: CC‐292 is a potent, selective, orally administered small molecule inhibitor of bruton tyrosine kinase (BTK). The aim of this study was to evaluate the relative bioavailability of newly developed CC‐292 tablet formulation (P22 tablet (P22‐TAB) and CC‐292 capsule formulati...

Full description

Bibliographic Details

Published in:	Journal of Clinical Pharmacy & Therapeutics Vol. 47; no. 8; pp. 1186 - 1194
Main Authors:	Cheng, Yiming, Liu, Liangang, Xue, Yongjun, Zhou, Simon, Li, Yan
Format:	research tables/charts randomized controlled trial Journal Article
Published:	Wiley-Blackwell Aug2022
Online Access:	View this record in EBSCOhost